The conversation discusses hair regrowth treatments, including stemcell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.
Adipose-derived stemcell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.
PP405 shows promise in hair loss treatment, but stemcell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stemcell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
Microneedling may enhance hair regrowth by transferring stem cells to dormant follicles, improving the effects of minoxidil. Users discuss using microneedling with needle lengths around 1.5mm to stimulate hair growth.
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
A stemcell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.
Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.
The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
The conversation is about someone seeking advice on choosing between stemcell therapy and PRP for treating hair loss, asking for personal results, side effects, overall satisfaction, and recommendations from others.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
Microneedling should target depths of 0.5mm to 1.5mm for hair loss, with weekly sessions at 1mm recommended. Combining microneedling with Minoxidil is common for improved results.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
Microneedling stimulates hair growth through stemcell activation during wound healing, not just increased blood flow. Other methods like showers or supplements don't replicate this effect.
Gene editing for hair loss is not yet viable due to technological and economic challenges. Current treatments like Minoxidil, finasteride, and hair transplants remain the most practical options.
The user has been using topical finasteride and minoxidil for two years with decent regrowth and recently added microneedling to their routine. They are questioning if the small hairs observed are new regrowth from microneedling or just vellus or miniaturized hairs.
PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.
Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stemcell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.
Stemcell treatment research shows promise in reversing hair loss in mice, but it's likely 10 years away and expensive. Current recommended treatments include minoxidil, finasteride, and hair transplants.
Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.
User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.